Puri-nethol

[Product name] Mercaptopurine tablets

[Trade name/trademark] Puri-nethol

[Specification] 50mg*25 tablets

[Main ingredient] Mercaptopurine.

[Characteristics] Mercaptopurine tablets are light yellow tablets.

[Functional Indications/Indications] Suitable for chorioepithelial carcinoma, malignant mole, acute lymphoblastic leukemia and acute non-lymphocytic leukemia, and the blast phase of chronic myelogenous leukemia.

[Usage and Dosage] 1. Chorioepithelial carcinoma: The usual dosage for adults is 6 mg to 6.5 mg/kg per day, taken orally in two doses, with 10 days as a course of treatment, and the interval between courses is 3 to 4 weeks. 2. Leukemia: (1) Initially, take 2.5 mg/kg or 80-100 mg/m2 daily, once a day or in divided doses. Generally, significant effects will be seen 2 to 4 weeks after treatment. If there is no clinical improvement after 4 weeks of treatment, If the number of white blood cells decreases, you may consider increasing the dose to 5 mg/kg per day under careful observation; (2) Maintenance, 1.5 mg to 2.5 mg/kg or 50 mg to 100 mg/m2 per day, taken orally once a day or in divided doses.

[Adverse reactions] 1. The more common ones are bone marrow suppression: white blood cells and thrombocytopenia may occur; 2. Liver damage: it may cause cholestasis and jaundice; 3. Digestive system: nausea, vomiting, loss of appetite, stomatitis, and diarrhea, but they occur less frequently and can be seen in patients who take too much medication. 4. Hyperuricemia: more common in the early stages of leukemia treatment, and uric acid nephropathy may occur in severe cases; 5. Interstitial pneumonia and pulmonary fibrosis are rare.

[Contraindications] People with liver and kidney dysfunction should use with caution; pregnant women are prohibited from taking this product.

[Notes] 1. Interference with diagnosis: A large number of leukemia cells are destroyed in leukemia, and even more are destroyed when taking mercaptopurine tablets, resulting in a significant increase in the concentration of uric acid in the blood and urine, and in severe cases, urate kidney stones may occur; 2. It should be used with caution in the following situations: the bone marrow has significant suppression (leukopenia or platelets are significantly reduced) or there is a corresponding serious infection or obvious Bleeding tendency; patients with liver function impairment, biliary disease, a history of gout, and urate kidney stones; those who have received cytotoxic drugs or radiotherapy within 4 to 6 weeks; 3. During the medication period, attention should be paid to regular inspections of peripheral blood and liver and kidney functions. White blood cell count and classification, platelet count, and hemoglobin should be followed up 1 to 2 times a week. For those whose blood cells drop sharply in a short period of time, blood images should be observed daily.

[Drug Interactions] 1. When taken together with allopurine, the latter inhibits the metabolism of mercaptopurine, which significantly increases the efficacy and toxicity of mercaptopurine; 2. When taken simultaneously with drugs that are toxic to liver cells, there is a risk of increased toxicity to liver cells; 3. When used in combination with other anti-tumor drugs or radiotherapy that suppress the bone marrow, the effect of mercaptopurine will be enhanced, so the dosage and course of treatment of mercaptopurine tablets must be considered to adjust.

[Drugs for pregnant and lactating women] Mercaptopurine tablets may increase the risk of fetal death and congenital malformations, so they are contraindicated during pregnancy.

[Medication for Elderly Patients] Since elderly patients have poor tolerance to chemotherapy drugs, when taking mercaptopurine tablets, supportive therapy must be strengthened and symptoms, signs, and dynamic changes in peripheral blood vessels must be closely observed.

[Pediatric Medication] Common dosage for children: 1.5mg~2.5mg/kg or 50mg/m2 daily, once a day or in divided doses.